Stonehaven Incubate has appointed Dr Ellie Virtue as Investment Manager. Dr Virtue is a scientific and commercial professional with experience in start-up human and veterinary biotech companies. She has provided consulting and business services to early-stage human, veterinary and agtech companies where her roles have included a wide range of functions including operations, commercialization, R&D and project management and partnership governance.
Stonehaven Incubate CEO, Dr Mark Heffernan, believes that Dr Virtue has a skillset and experience that fits perfectly with the company’s mission.
“We are really pleased to welcome Ellie to the team. Her broad experience and versatility across all business functions, combined with her academic background in virology, mean that she is a perfect match for the Stonehaven Incubate team as we evaluate new opportunities, spin out new businesses and build them from the ground up.
“Initially she will be assisting in deep technical and commercial evaluations of new global opportunities, and will be based in Melbourne.”
Dr Virtue has a Masters in Applied Finance from Macquarie University and a PhD from University of Melbourne. Her research on zoonotic viruses was conducted at the Australian Animal Health Laboratory, the country’s leading high-containment biosecurity facility. From 2011 until 2017 she worked for the animal health monoclonal antibody company, Nexvet Biopharma, where her roles encompassed research and development, operations, alliance management and business development.
ends
Notes to editor:
Formed in February 2018, Stonehaven Incubate is headquartered in Switzerland. Its parent company, Stonehaven Holdings AG, was founded in 2015 by George Gunn, former CEO of Novartis AH.
For more information contact Mike Keeler at Garnett Keeler PR on +44 (0)20 8647 4467 or mike.keeler@garnettkeeler.com or visit www.stonehaven-incubate.com
STO/008/18
